Clinical Trial: Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06931080) titled 'Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients' on April 09.

Brief Summary: The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Attention Deficit Hyperactivity Disorder (ADHD)

Intervention: DRUG: EB-1020 (Centanafadine) 164.4 mg

164.4 mg, capsule, oral, once daily, for 6 weeks

DRUG: EB-1020 (Centanafadine) 328.8 mg

328.8 mg, capsule, oral, once daily, for 6 weeks

DRUG: Placebo

Placebo, capsule, oral, once daily, f...